Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 604 results
Filters: First Letter Of Title is S  [Clear All Filters]
Found 604 results.

Acquired Immunodeficiency Syndrome

Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.

Adult

Gulick RM, Wilkin TJ, Chen YQ, et al. "Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial." Ann. Intern. Med.. 2017;167(6):384-393.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Dubé MP, Wu JW, Aberg JA, et al. "Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148." Antivir. Ther. (Lond.). 2006;11(8):1081-9.
Asmuth DM, Murphy RL, Rosenkranz SL, et al. "Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial." J. Infect. Dis.. 2010;201(11):1686-96.
Haas DW, Kwara A, Richardson DM, et al. "Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes." J. Antimicrob. Chemother.. 2014;69(8):2175-82.
Meier A, J Chang J, Chan ES, et al. "Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1." Nat. Med.. 2009;15(8):955-9.
Sandler NG, Zhang X, Bosch RJ, et al. "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection." J. Infect. Dis.. 2014;210(10):1549-54.
Hogan CM, Degruttola V, Sun X, et al. "The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals." J. Infect. Dis.. 2012;205(1):87-96.
Davey RT, Pertel PE, Benson A, et al. "Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy." J. Interferon Cytokine Res.. 2008;28(2):89-100.
Kalayjian RC, Franceschini N, Gupta SK, et al. "Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease." AIDS. 2008;22(4):481-7.
Evans SR, Yeh T-min, Sacktor N, et al. "Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090." HIV Clin Trials. 2007;8(6):437-46.
D Watts H, Park J-G, Cohn SE, et al. "Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093." Contraception. 2008;77(2):84-90.
Tenorio AR, Zheng Y, Bosch RJ, et al. "Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment." J. Infect. Dis.. 2014;210(8):1248-59.
Dooley KE, Park J-G, Swindells S, et al. "Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267." J. Acquir. Immune Defic. Syndr.. 2012;59(5):455-62.
Grinsztejn B, Smeaton L, Barnett R, et al. "Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count." Antivir. Ther. (Lond.). 2011;16(7):1057-62.
Rosenberg ES, Graham BS, Chan ES, et al. "Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection." PLoS ONE. 2010;5(5):e10555.
Umeh OC, Currier JS, Park J-G, Cramer Y, Hermes AE, Fletcher CV. "Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men." J Clin Pharmacol. 2011;51(12):1665-73.
Naggie S, Marks KM, Hughes M, et al. "Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C." Clin. Infect. Dis.. 2017;64(8):1035-1042.
Palmer S, Boltz V, Maldarelli F, et al. "Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy." AIDS. 2006;20(5):701-10.
Venuto CS, Mollan K, Ma Q, et al. "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202." J. Antimicrob. Chemother.. 2014;69(12):3300-10.

Pages